Novel radiation-enhancing agents in malignant gliomas

Seminars in Radiation Oncology

Volumn 16, Issue 1, 2006, Pages 29-37

  Zhang, Min ^a   Chakravarti, Arnab ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ANTINEOPLASTIC AGENT; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LOMUSTINE; NITROSOUREA; PROCARBAZINE; RAPAMYCIN DERIVATIVE; TEMOZOLOMIDE; TEMSIROLIMUS; VATALANIB; VINCRISTINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; ASTROCYTOMA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FATIGUE; FEBRILE NEUTROPENIA; GLIOBLASTOMA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; LEUKOPENIA; LYMPHOCYTOPENIA; META ANALYSIS; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; RASH; REVIEW; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 29344470775     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2005.08.004     Document Type: Article

References (45)

1. R. Stupp, W.P. Mason, M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
2. M.D. Walker, E. Alexander, W.E. Hunt Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas J Neurosurg 49 1978 333 343
3. M.D. Walker, S.B. Green, D.P. Byar Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant gliomas after surgery N Engl J Med 303 1980 1323 1329
4. E.A. Maher, F.B. Furnari, R.M. Bachoo Malignant glioma Genetics and biology of a grave matter Genes Dev 15 2001 1311 1333
5. H. Fine, K.B. Dear, J.S. Loeffler Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults Cancer 71 1993 2585 2597
6. L.A. Stewart Chemotherapy in adult high-grade glioma A systematic review and meta-analysis of individual patient data from 12 randomised trials Lancet 359 2002 1011 1018
7. M.R.C.B.T.W. Party Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma A Medical Research Council trial J Clin Oncol 19 2001 509 518
8. E.S. Newlands, M.F. Stevens, S.R. Wedge Temozolomide A review of its discovery, chemical properties, pre-clinical development, and clinical trials Cancer Treat Rev 23 1997 35 61
9. S.R. Wedge, J.K. Porteous, M.G. Glaser In vitro evaluation of temozolomide combined with X-irradiation Anticancer Drugs 8 1997 92 97
10. E.S. Newlands, G. Blackledge, R.S. Slack Phase I trial of temozolomide (CCRG 81045: M&B 39831:NSC 362856) Br J Cancer 65 1992 287 291
11. W.K. Yung, R.E. Albright, J. Olson A phase II study of temozolomide vs. procarbazine in patients with glioblastoma at first relapse Br J Cancer 83 2000 588 593
12. R. Stupp, P.Y. Dietrich, K.S. Ostermann Promising survival for patients with newly-diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide J Clin Oncol 20 2002 1375 1382
13. M.E. Hegi, A.C. Diserens, T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
14. P.O. Hackel, E. Zwick, N. Prenzel Epidermal growth factor receptors Critical mediators of multiple receptor pathways Curr Opin Cell Biol 11 1999 184 189
15. J.R. Woodburn The epidermal growth factor receptor and its inhibition in cancer therapy Pharmacol. Ther 82 1999 241 250
16. E. Zwick, P.O. Hackel, N. Prenzel The EGF receptor as central transducer of heterologous signalling systems Trends Pharmacol Sci 20 1999 408 412
17. K. Ang, B.A. Berkey, X. Tu Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res 62 2002 7350 7356
18. J. Baselga, J. Albanell Targeting epidermal growth factor receptor in lung cancer Curr Oncol Rep 4 2002 317 324
19. J. Baselga Why the epidermal growth factor receptor? The rationale for cancer therapy Oncologist 7 suppl 4 2002 2 8
20. N. Balaban, J. Moni, M. Shannon The effect of ionizing radiation on signal transduction Antibodies to EGF receptor sensitize A431 cells to radiation Biochim Biophys Acta 1314 1996 147 156
21. A. Chakravarti, A. Dicker, M. Mehta The contribution of EGFR signaling in human gliomas A review of preclinical and correlative data Int J Radiat Oncol Biol Phys 58 2004 927 931
22. A. Chakravarti, J.S. Loeffler, N.J. Dyson Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through the continued activation of phosphoinositide 3-kinase signaling Cancer Res 62 2002 200 207
23. A. Chakravarti, A. Chakladar, M.A. Delaney The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a ras-dependent manner Cancer Res 62 2002 4307 4315
24. F. Ciardiello, R. Bianco, V. Damiano Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells Clin Cancer Res 6 2000 3739 3747
25. F. Ciardiello Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents Drugs 60 suppl 1 2000 25 32 discussion 41-42
26. P. Dent, D.B. Reardon, J.S. Park Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death Mol Biol Cell 10 1999 2493 2506
27. F.G. Barker, M.L. Simmons, S.M. Chang EGFR overexpression and radiation response in glioblastoma multiforme Int J Radiat Oncol Biol Phys 51 2001 410 418
28. N. Shinojima, K. Tada, S. Shiraishi Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme Cancer Res 63 2003 6962 6970
29. A. Chakravarti, M.A. Delaney, E. Noll Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas Clin Cancer Res 7 2001 2387 2395
30. M.-C. Etienne, J.L. Formento, C. Lebrun-Frenay Epidermal growth factor receptor and labeling index are independent prognostic factors in glial turmor outcome Clin Cancer Res 4 1998 2383 2390
31. M.M. Feldkamp, P. Lala, N. Lau Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens Neurosurgery 45 1999 1442 1453
32. J.S. Smith, I. Tachibana, S.M. Passe PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme J Nat Cancer Inst 93 2001 1246 1256
33. N.G. Rainov, K.U. Dobberstein, H. Bahn Prognostic factors in malignant glioma Influence of the overexpression of oncogene and tumor-suppressor gene products on survival J Neurooncol 35 1997 13 28
34. A. Chakravarti, W. Seiferheld, X. Tu Immunohistochemically determined total EGFR levels are not of prognostic value in newly diagnosed GBM A report from the Radiation Therapy Oncology Group Int J Radiat Oncol Biol Phys 62 2005 318 327
35. J.C. Buckner Immunohistochemical detection of EGFRvIII and prognostic significance in patinets with malignant glioma enrolled in NCCTG clinical trials J Clin Oncol 22 2004 1508
36. M. Prados Phase I study of ZD1839 plus temozolomide in patients with malignant glioma J Clin Oncol 22 2004 1504
37. J. Rich, D.A. Reardon, T. Peery Phase II trial of gefitinib in recurrent glioblastoma J Clin Oncol 22 2004 133 142
38. M. Prados Phase I study of OSI-774 alone or with temozolamide in patients with malignant glioma Proc Am Soc Clin Oncol 22 2003 99
39. J.J. Raizer A phase II trial of erlotinib (OSI-774) in patients with recurrent malignant gliomas not on EIACDs J Clin Oncol 22 2004 1502
40. A. Chakravarti, G. Zhai, Y. Suzuki The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas J Clin Oncol 22 2004 1926 1933
41. A. Chakravarti, J.S. Loeffler, N.J. Dyson Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of physphoinositide 3-kinase signaling Cancer Res 62 2002 200 207
42. A. Chakravarti An update of phase I data from RTOG 0211 A phase I/II clinical study of gefitinib+radiation for newly-diagnosed GBM patients J Clin Oncol 22 2004 1571
43. E. Galanis NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM) J Clin Oncol 22 2004 1503
44. C. Conrad A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent GBM J Clin Oncol 22 2004 1512
45. D.A. Reardon A phase I/II trial of PTK-787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with either temozolomide or lomustine for patients with recurrent GBM J Clin Oncol 22 2004 1513